Pfizer Terminates Development of Sangamo’s Hemophilia A Gene Therapy, Returning Full Rights to Sangamo

Termination of Collaboration:
Pfizer has ended its collaboration with Sangamo Therapeutics on the development of giroctocogene fitelparvovec, a gene therapy for hemophilia A, despite positive Phase 3 trial results12.

Rights Reversion:
Sangamo Therapeutics will regain full rights to the hemophilia A gene therapy program, effective immediately2.

Future Plans:
Sangamo plans to explore all options to commercialize giroctocogene fitelparvovec, including seeking a new collaboration partner2.

Phase 3 AFFINE Trial:
The trial demonstrated the potential of giroctocogene fitelparvovec as a life-changing treatment for hemophilia A patients, meeting primary and secondary endpoints2.

Regulatory Submissions:
Sangamo believes giroctocogene fitelparvovec is well-positioned for regulatory submissions and potential commercialization2.

Sources:

1. https://endpts.com/pfizer-ends-work-on-sangamos-hemophilia-gene-therapy-crushing-biotechs-hopes/

2. https://investor.sangamo.com/news-releases/news-release-details/sangamo-therapeutics-regain-full-rights-hemophilia-gene-therapy